Healthcare >> CEO Interviews >> October 14, 2002
NIGEL L. WEBB, Chairman, President and CEO of Protarga, Inc., has 30
years of experience with the healthcare industry in the United States
and Europe. From 1972 through 1982, he directed product development and
marketing programs for large pharmaceutical companies (Searle, Johnson &
Johnson). From 1982 through the present, Dr. Webb has served on the
Boards of six healthcare companies, and acted as President for the
start-up of two biotechnology companies (Damon Biotech and Hybridon). He
was appointed by the Governor of Massachusetts to the state
biotechnology board, and he served on the Executive Committee of the US
biotechnology trade association. Dr. Webb was awarded his MA in
Biochemistry from Cambridge University, and his PhD for research into
the structure of nucleic acids in the M.R.C. laboratory of Nobel
laureate Maurice Wilkins. Dr. Webb is the coinventor of a number of
pharmaceutical products, including Protarga's new cancer drug
Taxoprexin' that will enter Phase III clinical studies in 2002. Profile
would you give us a picture of things as they are now?
Dr. Webb: The company began operations in 1993 to commercialize
